Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | BRD2 | P25440 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239499 | 0.92 | KMT2A (0.54) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL9525522 | 0.88 | CA5A (0.57) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL9525773 | 0.88 | KMT2A (0.54) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL22946249 | 0.87 | PARP10 (0.58) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL3022780 | 0.87 | KAT6A (0.49) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL1188166 | 0.85 | KMT2A (0.48) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL1190221 | 0.84 | CREBBP (0.47) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL22945638 | 0.84 | ALDH1A1 (0.56) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL22945926 | 0.84 | PLK1 (0.60) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL31634959 | 0.84 | PLK1 (0.60) | KMT2AMEN1CREBBPBRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230192749-A1 | PROTECTED FLUORESCENT REAGENT COMPOUNDS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2021020429-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | 大正製薬株式会社 | 2021-02-04 | — | — | WO | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-9957291-B2 | Protected fluorescent reagent compounds | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| CN-104974135-B | Targeting DNA has the Sai-Mi-Xi-Bu derivative containing benzene-naphthalene diimide structure of antitumor activity, pharmaceutical composition and its preparation method and application | 河北大学 | 2017-03-08 | — | — | CN | disclosed |
| US-20160237279-A1 | MULTIMERIC PROTECTED FLUORESCENT REAGENTS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2222681-B1 | EFFICIENT ASPIRIN PRODRUGS | PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-02-17 | — | — | EP | disclosed |
| US-20150050659-A1 | PROTECTED FLUORESCENT REAGENT COMPOUNDS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8486974-B2 | Efficient aspirin prodrugs | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2013-07-16 | — | — | US | disclosed |
| US-8486974-B2 | Efficient aspirin prodrugs | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2013-07-16 | — | — | US | disclosed |
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2011-02-24 | — | — | US | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | KMT2A 3137/4885MEN1 1465/4885CREBBP 2375/4885 |
| US-20150050659-A1 | PROTECTED FLUORESCENT REAGENT COMPOUNDS | ERCC4, ERCC2, ERCC1 | KMT2A 1933/4885MEN1 2015/4885CREBBP 1547/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | KMT2A 3137/4885MEN1 1465/4885CREBBP 2375/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | KMT2A 3137/4885MEN1 1465/4885CREBBP 2375/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | KMT2A 3137/4885MEN1 1465/4885CREBBP 2375/4885 |
| US-20230192749-A1 | PROTECTED FLUORESCENT REAGENT COMPOUNDS | ERCC4, ERCC2, ERCC1 | KMT2A 1933/4885MEN1 2015/4885CREBBP 1547/4885 |
| US-20110046182-A1 | EFFICIENT ASPIRIN PRODRUGS | COX15, PTGS1, CYP3A43 | KMT2A 4796/4885MEN1 3818/4885CREBBP 2717/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | KMT2A 1250/4885MEN1 848/4885CREBBP 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.